Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Boyer

Showing results (21-30 of 134) with videos related to

Pageof 14
Sort By:
Translational Vision Science & Technology|March 17, 2017
Variability of Retinal Thickness Measurements in Tilted or Stretched Optical Coherence Tomography ImagesAkihito Uji, Nizar Saleh Abdelfattah, David S Boyer, et al.
Ophthalmology. Retina|April 2, 2019
Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World EvidenceUsha Chakravarthy, Vladimir Bezlyak, Alexandros Sagkriotis, et al.
Journal of Cataract and Refractive Surgery|January 31, 2012
Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapyHomayoun Tabandeh, Nauman A Chaudhry, David S Boyer, et al.
Retina (Philadelphia, Pa.)|October 7, 2010
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor studySrinivas R Sadda, Glenn Stoller, David S Boyer, et al.
Journal of Glaucoma|November 19, 2013
Methyl-sulfonyl-methane (MSM)-induced acute angle closureJeremy C Hwang, Kay T Khine, Jennifer C Lee, et al.
Retina (Philadelphia, Pa.)|December 1, 2016
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGETDavid S Boyer, Ursula Schmidt-Erfurth, Menno van Lookeren Campagne, et al.
American Journal of Ophthalmology|June 19, 2017
Postreceptor Neuronal Loss in Intermediate Age-related Macular DegenerationEnrico Borrelli, Nizar Saleh Abdelfattah, Akihito Uji, et al.
Ophthalmology|March 27, 2012
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI studyPeter K Kaiser, David S Boyer, Alan F Cruess, et al.
Eye (London, England)|May 28, 2024
ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathyQuan Dong Nguyen, Justis P Ehlers, David S Boyer, et al.
BMJ Open Ophthalmology|February 3, 2026
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a studySunil S Patel, David S Boyer, Anat Loewenstein, et al.
Pageof 14

Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Translational Vision Science & Technology|March 17, 2017
Variability of Retinal Thickness Measurements in Tilted or Stretched Optical Coherence Tomography ImagesAkihito Uji, Nizar Saleh Abdelfattah, David S Boyer, et al.
Ophthalmology. Retina|April 2, 2019
Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World EvidenceUsha Chakravarthy, Vladimir Bezlyak, Alexandros Sagkriotis, et al.
Journal of Cataract and Refractive Surgery|January 31, 2012
Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapyHomayoun Tabandeh, Nauman A Chaudhry, David S Boyer, et al.
Retina (Philadelphia, Pa.)|October 7, 2010
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor studySrinivas R Sadda, Glenn Stoller, David S Boyer, et al.
Journal of Glaucoma|November 19, 2013
Methyl-sulfonyl-methane (MSM)-induced acute angle closureJeremy C Hwang, Kay T Khine, Jennifer C Lee, et al.
Retina (Philadelphia, Pa.)|December 1, 2016
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGETDavid S Boyer, Ursula Schmidt-Erfurth, Menno van Lookeren Campagne, et al.
American Journal of Ophthalmology|June 19, 2017
Postreceptor Neuronal Loss in Intermediate Age-related Macular DegenerationEnrico Borrelli, Nizar Saleh Abdelfattah, Akihito Uji, et al.
Ophthalmology|March 27, 2012
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI studyPeter K Kaiser, David S Boyer, Alan F Cruess, et al.
Eye (London, England)|May 28, 2024
ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathyQuan Dong Nguyen, Justis P Ehlers, David S Boyer, et al.
BMJ Open Ophthalmology|February 3, 2026
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a studySunil S Patel, David S Boyer, Anat Loewenstein, et al.
Pageof 14